Tumor-agnostic baskets to N-of-1 platform trials and real-world data: Transforming precision oncology clinical trial design

Historically, patients afflicted with cancer are treated on the basis of their histological subtype and the site of origin for their malignancy, as determined by the light microscope. However, rapid advances in the ability to interrogate cancers based on genomic/transcriptomic sequencing have yielded clinical-grade tests, almost unthinkable just a few years ago, which can interrogate each tumor ’s multi-omic and immune profile and identify its distinct molecular signature. This information can now be exploited in the clinic to provide precise, personalized therapeutic options.
Source: Cancer Treatment Reviews - Category: Cancer & Oncology Authors: Source Type: research